PeerVoice Clinical Pharmacology Audio

PeerVoice is committed to producing and distributing evidence-based, independently-created medical education in Clinical Pharmacology that is designed to positively impact patient care. Activities can either be accredited or non-accredited but are always driven by the learning and practice needs of healthcare professionals. Learn more at: https://peervoice.com.

206 episodes

15d ago latest

weekly cadence

English language

▶ Play latestRSS feed Website Science Health Fitness Medicine Education

https://c.peervoice.com/podcast/xml/clinical_pharmacology_audio.xml

Episodes 207

Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices
2d ago · 38:31
For the complete activity, including supporting material, please visit https://www.peervoice.com/CTG860. Presented by Hannele Yki-Järvinen, MD, FRCP and Jeremy Tomlinson, MD, PhD, FRCP. Learning Objectives: Identify individuals who warrant evaluation for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis based on the presence of cardiometabolic risk factors; Apply available non-invasive scoring systems such as the Fibrosis-4 (FIB-4) Index to predict presence of hepatic fibrosis; Use the outcomes of non-invasive tests to guide referral of individuals to specialist care for su
Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes
2d ago · 1:01:39
For the complete activity, including supporting material, please visit https://www.peervoice.com/TNJ860. Presented by Jeffrey Weitz, MD, OC, FRCP(C); Charlotte Cordonnier, MD, PhD; and Mike Sharma, MD, MSc, FRCPC. Learning Objectives: Describe the rationale for FXIa inhibition for reducing the risk of secondary stroke, including the relative importance of this coagulation factor in haemostasis, thrombosis and real-world data from people living with high/low levels of FXIRecall the results of clinical trials evaluating FXIa inhibitors for secondary stroke prevention after non-cardioembolic isch
Luis Querol, MD, PhD - CIDP at a Crossroads: Addressing the Burden of Suboptimal Care and the Need for Therapeutic Advancement
15d ago · 19:20
For the complete activity, including supporting material, please visit https://www.peervoice.com/RZR860. Presented by Luis Querol, MD, PhD and Jean-Philippe Plançon. Learning Objectives: Describe the multifaceted impact of chronic inflammatory demyelinating polyneuropathy (CIDP); Explain the limitations of established treatment strategies for CIDP that are driving the need for treatment innovations; Recognise the most recently approved and emerging treatment approaches for CIDP.
Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes
15d ago · 32:12
For the complete activity, including supporting material, please visit https://www.peervoice.com/KGV860. Presented by Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP; Amer Durrani, FRCS (Plast); and Philip Albery, LLB. Learning Objectives: Identify the unmet needs in the management of high-risk cutaneous squamous cell carcinoma (CSCC), including the challenges and morbidity associated with existing interventions; Assess patient preferences and quality-of-life considerations when making treatment decisions, including the impact on physical and mental wellbeing; Evaluate data from tri
One Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings
1mo ago · 26:33
For the complete activity, including supporting material, please visit https://www.peervoice.com/GVP860. Presented by Miguel Bajouco, MD, MSc; David Cassiman, MD, PhD; Rebecca Karp Leaf, MD; Katherine Pocius, MD, MPH; and Paulo Lima Serrano, MD, PhD Learning Objectives: Recognise the importance of early suspicion of acute hepatic porphyria (AHP) in reducing diagnostic delays and improving outcomes; Explain how to test for AHP in patients with indicative clinical symptoms and signs; Analyse presenting symptoms and clinical history to determine when AHP should be strongly suspected and diagnosti
John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community
1mo ago · 17:39
For the complete activity, including supporting material, please visit https://www.peervoice.com/WBP860. Presented by John Friedewald, MD, FASN, FAST Learning Objectives: Identify emerging data that can be applied in current clinical practice to optimize the care and outcomes of kidney transplant recipients; Evaluate investigational immunosuppressants, therapies and technologies, and overall research trends to anticipate potential shifts in future standards of care in kidney transplantation.
Kausik Ray, MD, MPhil (Cantab), FMedSci - Altering the Disease Trajectory in Patients With and at High Risk of Atherosclerotic Cardiovascular Disease: Ensuring Best Practices for Identification and Management
1mo ago · 16:39
For the complete activity, including supporting material, please visit https://www.peervoice.com/VUR860. Presented by Kausik Ray, MD, MPhil (Cantab), FMedSci. Learning Objectives: Discuss the rationale and importance of earlier recognition of patients with and at high risk of atherosclerotic cardiovascular disease (ASCVD); Identify key features associated with high-risk ASCVD; Apply practical strategies for achieving effective lipid control in individuals at high risk of ASCVD.
Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health
2mo ago · 1:17:14
For the complete activity, including supporting material, please visit https://www.peervoice.com/VAC860. Presented by Carel le Roux, MBChB, MSc, PhD; Biykem Bozkurt, MD, PhD; Domenica M. Rubino, MD; and Michael Donnelly-Boylen, MS. Learning Objectives: Describe the pathophysiologic relationship between obesity, metabolic dysfunction, and end-organ injury across cardiovascular, renal, and metabolic disease; Evaluate key clinical and psychosocial factors that influence multidisciplinary management decisions for patients with obesity and related cardiovascular-renal-metabolic disease; Apply evide
Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease
2mo ago · 25:41
For the complete activity, including supporting material, please visit https://www.peervoice.com/YWG860. Presented by Hannele Yki-Järvinen, MD, FRCP and Cyrielle Caussy, MD, PhD. Learning Objectives: Recognise the bidirectional relationship between type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH), including the impact of MASH on glycaemic control, insulin resistance, and complications; Explain the rationale for prompt identification and active management of individuals with MASH and fibrosis, based on the increased risk of adverse liver outcomes associated with
David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World
2mo ago · 20:43
For the complete activity, including supporting material, please visit https://www.peervoice.com/DMZ860. Presented by David Alain Wohl, MD; and Antonella Castagna, MD. Learning Objectives: Explain the clinical rationale for rapid antiretroviral therapy (ART) in people with HIV; Evaluate evidence on the benefits and limitations of rapid ART in HIV; Formulate practical steps to align rapid ART practices in HIV with both guideline expectations and real-world realities.
Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge
2mo ago · 18:45
For the complete activity, including supporting material, please visit https://www.peervoice.com/TPE860. Presented by Silvia Stacchiotti, MD and Michiel van de Sande, MD, PhD. Learning Objectives: Describe the clinical evidence supporting emerging systemic therapies for tenosynovial giant cell tumour (TGCT); Identify factors that influence decisions on whether to opt for systemic treatment versus surgical intervention; Analyse case scenarios to propose evidence-based treatment plans for patients with TGCT.
Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer
2mo ago · 19:41
For the complete activity, including supporting material, please visit https://www.peervoice.com/CFH860. Presented by Javier Cortés, MD, PhD and Laura Huppert, MD. Learning Objectives: Recall the results of clinical trials evaluating TROP2-directed antibody-drug conjugates (ADCs) as monotherapy or in combination with a PD-1 inhibitor in frontline treatment settings of HR+/HER2- or triple-negative metastatic breast cancer (TNBC); Assess the potential clinical impact of these data, including patient populations included in trials and how these relate to patients seen in the real-world clinic..
Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer
3mo ago · 54:23
For the complete activity, including supporting material, please visit https://www.peervoice.com/UGY860. Presented by Trisha Wise-Draper, MD, PhD; Christine H. Chung, MD; Renata Ferrarotto, MD; and Kevin Harrington, PhD, FRCP, FRCR. Learning Objectives: Explain the implications of human papillomavirus (HPV) status in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) for patient outcomes and quality of life; Interpret clinical trial data stratified by HPV status to identify limitations of current standard-of-care therapies for non-HPV–associated recurrent/metastatic HNSCC; Expl
Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice
3mo ago · 35:42
For the complete activity, including supporting material, please visit https://www.peervoice.com/FAK860. Presented by Sven Francque, MD, PhD; and José Luis Calleja Panero, MD, PhD. Learning Objectives: Recall the rationale for prompt identification of metabolic dysfunction-associated steatohepatitis (MASH) in gastroenterology patients, including the high prevalence in specific patient groups, the risk of progression, and the availability of novel treatments; Use recommended non-invasive blood- and image-based methods to evaluate for evidence of steatosis and fibrosis among individuals with car
Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional
3mo ago · 1:20:09
For the complete activity, including supporting material, please visit https://www.peervoice.com/ZRT860. Presented by Anjali Tiku Owens, MD; Andrew Willeford, PharmD, PhD, BCCP; and Rachel Lavelle, PharmD, BCCP Learning Objectives: Differentiate between obstructive and non-obstructive hypertrophic cardiomyopathy (oHCM and nHCM) based on their pathophysiology and current guideline-directed management strategies; Evaluate the efficacy and safety of cardiac myosin inhibition as monotherapy or first-line therapy for oHCM in comparison to beta-blockade; Compare available cardiac myosin inhibitors (
Mike Sharma, MD, MSc, FRCPC - Deepening the Dialogue on the Latest Data for Factor XIa Inhibition: Is It Time to Shift the Paradigm in Secondary Stroke Prevention?
4mo ago · 1:15:47
For the complete activity, including supporting material, please visit https://www.peervoice.com/GWR860. Presented by Mike Sharma, MD, MSc, FRCPC; Xin Cheng, MD, PhD; Emiliya Melkumova, MD; and Roland Veltkamp, MD. Learning Objectives: Evaluate efficacy and safety outcomes for Factor XIa (FXIa) inhibitors in the prevention of ischemic stroke following an acute non-cardioembolic ischemic stroke (NCIS) or high-risk transient ischemic attack (TIA); Identify patient-specific characteristics that may influence the efficacy or safety of FXIa inhibitors for secondary stroke prevention (SSP); Apply cu
Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition
4mo ago · 36:53
For the complete activity, including supporting material, please visit https://www.peervoice.com/FBM860. Presented by Xin Cheng, MD, PhD; Ashkan Shoamanesh, MD, FRCPC; and Jeffrey Weitz, MD, OC, FRCPC. Learning Objectives: Explain the rationale and potential role for Factor XIa inhibition in secondary prevention of non-cardioembolic ischaemic stroke (NCIS) or high-risk transient ischaemic attack (TIA); Recall the trial design, methodology, and inclusion criteria for key phase 3 trials of Factor XIa inhibitors in secondary stroke prevention (SSP) of NCIS or high-risk TIA; Evaluate clinical outc
Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes
4mo ago · 1:19:25
For the complete activity, including supporting material, please visit https://www.peervoice.com/ACQ860. Presented by Colin M. Dayan, MA, MBBS, FRCP, PhD; Michael J. Haller, MD; and Olga Kordonouri, MD. Learning Objectives: Explain the clinical rationale and existing evidence for use of immunomodulatory therapies to delay the progression of type 1 diabetes (T1D); Identify practical workflows and protocols that facilitate the potential integration of immunomodulatory infusions into endocrinology practice, including care pathways for T1D; Evaluate patient perspectives and considerations related
Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can
4mo ago · 20:02
For the complete activity, including supporting material, please visit https://www.peervoice.com/PXK860. Presented by Javier Ampuero, MD, PhD and Meena B. Bansal, MD, FAASLD. Learning Objectives: Explain the rationale for prompt identification and active management of individuals with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, based on the increased risk of adverse liver outcomes associated with progression of fibrosis; Evaluate the impact of novel MASH-targeted therapies, such as THR-β agonists, on the underlying pathophysiology and progression of the disease; Ident
Caterina Garone, MD, PhD - From Clinical Clues to a Confirmatory Diagnosis: Recognising Thymidine Kinase 2 Deficiency Across the Age Spectrum
4mo ago · 27:58
For the complete activity, including supporting material, please visit https://www.peervoice.com/KCZ860. Presented by Caterina Garone, MD, PhD and Noemi Speroni. Learning Objectives: Describe the pathophysiological basis and clinical spectrum of thymidine kinase 2 (TK2) deficiency to support earlier recognition in undiagnosed patients; Summarise the key steps in diagnosing TK2 deficiency, including when to use genetic and enzyme testing; Recognise clinical features of infantile-onset TK2 deficiency and differentiate them from other causes of neonatal hypotonia and respiratory failure; Apply ag
Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade
5mo ago · 29:29
For the complete activity, including supporting material, please visit https://www.peervoice.com/FAN860. Presented by Austin Kulasekararaj, MD, MRCP, FRCPath; and Bruno Fattizzo, MD Learning Objectives: Discuss the criticality of achieving and sustaining terminal complement inhibition in patients with paroxysmal nocturnal haemoglobinuria (PNH), and the evidence for C5 inhibitor therapy on key efficacy outcomes; Recognise that extravascular haemolysis (EVH) is a potential limitation of terminal complement inhibition with C5 inhibitors and the need to target proximal complement blockade in patie
Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era
5mo ago · 40:01
For the complete activity, including supporting material, please visit https://www.peervoice.com/KBA860. Presented by Jonathan W. Goldman, MD and Misty Dawn Shields, MD, PhD. Learning Objectives: Recall the current evidence base and guideline recommendations for the use of immunotherapy in small cell lung cancer (SCLC); Evaluate the rationale, evidence, and implications of emerging strategies for treatment of extensive-stage (ES)-SCLC, including use of combination therapy in the maintenance phase of first-line treatment; Identify relevant patient and disease-specific considerations that may gu
David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases
6mo ago · 36:03
For the complete activity, including supporting material, please visit https://www.peervoice.com/QDZ860. Presented by David Kavanagh, MBChB, PhD, FRCP; and Kerstin Amann, MD>. Learning Objectives: Identify key histopathological findings from renal biopsy specimens of patients with IgAN, C3G, and IC-MPGN; Describe how complement pathway dysregulation manifests in clinicopathological features of IgAN, C3G, and IC-MPGN; Apply evidence-based diagnostic technologies, including electron microscopy, to support accurate diagnosis in IgAN, C3G, and IC-MPGN; Utilise validated grading systems to assess d
Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?
6mo ago · 19:34
For the complete activity, including supporting material, please visit https://www.peervoice.com/GNV860. Presented by Cristina Saura Manich, MD, PhD and Aditya Bardia, MD. Learning Objectives: Evaluate the clinical data for emerging therapeutic strategies for the management of HER2+ metastatic breast cancer in the first-line setting; Discuss key learnings from clinical trials for investigative first-line treatment approaches for HER2+ metastatic breast cancer in context of different patient and disease characteristics.
Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients
6mo ago · 28:36
For the complete activity, including supporting material, please visit https://www.peervoice.com/SDW860. Presented by Yohei Doi, MD, PhD and Sarah Jarvis, MBE, FRCGP. Learning Objectives: Differentiate key clinical and demographic factors, including age, comorbidities, and immune status, that define high-risk COVID-19 patient profiles; Propose strategies to improve early identification of high-risk patients for appropriate COVID-19 treatment; Interpret regional epidemiological data from Europe and Asia-Pacific to contextualise risk profiles for diverse patient populations; Apply clinical crite

Episodes

Reading the feed…

Also on peervoice.com

More Science shows

Arizona Science

azpm.org

510 episodes · 9d ago

WiTcast

witcastthailand.com

357 episodes · 8d ago

Evrim Ağacı ile Bilime Dair Her Şey!

evrimagaci.org

557 episodes · 8d ago

A Moment of Science

prxu.org

1,000 episodes · 9d ago

Groks Science Radio Show and Podcast

ocf.berkeley.edu

1,000 episodes · 11d ago

Ask the Naked Scientists

thenakedscientists.com

802 episodes · 9d ago

PeerVoice Clinical Pharmacology Audio

Episodes 207

Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices

Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes

Luis Querol, MD, PhD - CIDP at a Crossroads: Addressing the Burden of Suboptimal Care and the Need for Therapeutic Advancement

Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes

One Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings

John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community

Kausik Ray, MD, MPhil (Cantab), FMedSci - Altering the Disease Trajectory in Patients With and at High Risk of Atherosclerotic Cardiovascular Disease: Ensuring Best Practices for Identification and Management

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease

David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World

Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Mike Sharma, MD, MSc, FRCPC - Deepening the Dialogue on the Latest Data for Factor XIa Inhibition: Is It Time to Shift the Paradigm in Secondary Stroke Prevention?

Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition

Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes

Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can

Caterina Garone, MD, PhD - From Clinical Clues to a Confirmatory Diagnosis: Recognising Thymidine Kinase 2 Deficiency Across the Age Spectrum

Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients

Episodes

Also on peervoice.com

PeerVoice Internal Medicine Video

PeerVoice Internal Medicine Audio

PeerVoice Clinical Pharmacology Video

PeerVoice Oncology & Haematology Video

PeerVoice Oncology & Haematology Audio

PeerVoice Endocrinology & Metabolic Disorders Video

More Science shows

Arizona Science

WiTcast

Evrim Ağacı ile Bilime Dair Her Şey!

A Moment of Science

Groks Science Radio Show and Podcast

Ask the Naked Scientists

Episodes 207

Hannele Yki-Järvinen, MD, FRCP - Recognising and Referring Individuals With MASH: Practical Pathways for Our Endocrinology Practices

Jeffrey Weitz, MD, OC, FRCP(C) - Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes

Luis Querol, MD, PhD - CIDP at a Crossroads: Addressing the Burden of Suboptimal Care and the Need for Therapeutic Advancement

Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes

One Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings

John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community

Kausik Ray, MD, MPhil (Cantab), FMedSci - Altering the Disease Trajectory in Patients With and at High Risk of Atherosclerotic Cardiovascular Disease: Ensuring Best Practices for Identification and Management

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease

David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World

Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Mike Sharma, MD, MSc, FRCPC - Deepening the Dialogue on the Latest Data for Factor XIa Inhibition: Is It Time to Shift the Paradigm in Secondary Stroke Prevention?

Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition

Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes

Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can

Caterina Garone, MD, PhD - From Clinical Clues to a Confirmatory Diagnosis: Recognising Thymidine Kinase 2 Deficiency Across the Age Spectrum

Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients